Navigation Links
Agendia Appoints Peter W. Schineller as Chief Commercial Officer
Date:6/3/2013

IRVINE, Calif. and AMSTERDAM, June 3, 2013 /PRNewswire/ -- Agendia, a leader in molecular cancer diagnostics, today announced the addition of Peter W. Schineller as its Chief Commercial Officer.  In this newly created position, Mr. Schineller will lead Agendia's global commercialization activities as it delivers technologies to translate personalized diagnostics into actionable, patient-centered solutions for clinicians. 

Mr. Schineller's 25-year professional career spans both the diagnostic and pharmaceutical industry.  Most recently, Mr. Schineller served as Senior Vice President and Chief Commercial Officer at Alexza Pharmaceuticals. Prior to that, he was Senior Vice President and General Manager at Ventana Medical Systems, a Roche company; and Senior Vice President Sales, Marketing and Commercial Operations, at Genoptix Medical Laboratories, acquired by Novartis. 

Mr. Schineller was also a co-founder at Verus Pharmaceuticals and held positions of increasing responsibility in sales and marketing with Abbott Laboratories, Dura/Elan and Cypress Bioscience.  Prior to entering the healthcare industry, Mr. Schineller served as a Commissioned Officer in the United States Marine Corps where he attained the rank of Captain.

"As we continue our growth momentum into 2013, we are committed to building out a world class organization capable of managing and growing a much larger company.  To that end, we are thrilled to add Peter Schineller to our executive team," said David Macdonald , Agendia's Chief Executive Officer. "Mr. Schineller's depth of experienced senior leadership of global commercial organizations will help us perpetuate our volume growth, which exceeded 140 percent in 2012."

About Agendia:
Agendia is a leading molecular diagnostic company that develops and markets FFPE-based genomic diagnostic products, which help support physicians with their complex treatment decisions. Agendia's breast cancer Symphony™ suite was developed using unbiased gene selection, analyzing the complete human genome, ensuring 100% definitive results for cancer patients.  Symphony includes MammaPrint, the first and only FDA-cleared IVDMIA breast cancer recurrence assay, as well as BluePrint­­®, a molecular subtyping assay, TargetPrint®, an ER/PR/HER2 expression assay, and TheraPrint®, an alternative therapy selection assay. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo, hormonal, or combination therapy, and which patients do not require these treatments and can instead be treated with other less arduous and less costly methods.

In addition to the Symphony suite of tests, Agendia has a rich pipeline of genomic products in development. The Company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and MINDACT trials.  For more information, please visit www.agendia.com.Contact:Matt Clawson or 

Liz Dowling (Medical & Consumer Media)Len Hall (Financial Media)

Dowling & Dennis Public RelationsAllen & Caron Inc. 949-474-4300

415-388-2794matt@allencaron.com 

Liz@DowlingDennis.netlen@allencaron.com   


'/>"/>
SOURCE Agendia
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Agendia Announces Nine Studies in Breast and Colon Cancer for Presentation at 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO)
2. Agendia Names Industry Veteran Glen Fredenberg CFO and Vice President of Finance
3. Agendia Earns ISO Certification for Facilities in Amsterdam and Irvine
4. Agendia Brings Together Thought Leaders in Molecular Diagnostics and Medical Oncology
5. Agendia Announces Five Studies in Breast Cancer for Presentation at the American Society of Clinical Oncology 2012 Breast Cancer Symposium
6. Agendia Appoints Dr. Neil M. Barth MD, FACP, as Chief Medical Officer
7. Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions
8. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
9. Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer
10. Nephros Appoints John C. Houghton as President and Chief Executive Officer
11. Elsevier Appoints New President of Elsevier CPM Resource Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy ... in the United States and Canada wear eyeglasses. Once considered to be a purely ... make a fashion statement. Even celebrities use glasses as a way of creating an ...
(Date:6/26/2016)... ... 2016 , ... PawPaws brand pet supplements owned by Whole Health ... the health of felines. The formula is all-natural and is made from Chinese herbs ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
Breaking Medicine News(10 mins):